Track market-moving stories before they get noisy

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification.

“The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and Global Head of R&D at Incyte.

Share These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884).

“The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and Global Head of Research and Development. “What distinguishes INCA033989 is its potential to deliver disease control while targeting the biology that drives it. We remain on track to initiate our pivotal ET study by mid-2026 and are actively engaging regulators on a pivotal MF program.”

Results in Patients with Myelofibrosis (MF)

The safety, tolerability, and efficacy of INCA033989 in Type 1 and non-Type 1 patients with MF harboring a CALR mutation is being evaluated in two ongoing Phase 1 studies. Results demonstrate that INCA033989 delivers broad, clinically meaningful improvements across spleen volume, symptom burden and anemia in patients with MF. As a monotherapy and in combination with ruxolitinib, INCA033989 had a manageable safety profile and the majority of patients remained on treatment – no dose-limiting toxicities were observed, and a maximum tolerated dose was not reached.

Monotherapy: INCA033989 was evaluated as monotherapy in patients who were resistant, refractory or intolerant to JAK inhibitor treatment after >12 weeks (JAK R/R/I), or ineligible to JAK inhibitor therapy. The dose escalation cohort evaluated INCA033989 from 24-3500 mg, and the dose expansion cohort evaluated 250 mg and 2000 mg.

INCA033989 monotherapy demonstrated durable clinical benefit, with clinically meaningful improvements across spleen volume, symptoms and anemia across both JAK R/R/I and JAK ineligible patients.

Spleen Volume Reduction (SVR): Rapid and robust spleen volume reductions were observed in patients, with 55% (38/69) and 39% (27/69) of patients achieving the best SVR25 and SVR35 reduction, respectively. At Week 24, 27% (17/62) patients achieved SVR35, including 47% (8/17) JAK ineligible and 20% (9/45) JAK R/R/I. Robust responses were observed in JAK ineligible patients regardless of mutation type (60% [6/10] Type-1 vs. 29% [2/7] non-Type 1). In JAK R/R/I patients, clinically meaningful reductions were observed in 31% (8/26) of Type-1 patients across all evaluated doses at Week 24, and 33% (1/3) of non-Type-1 patients evaluated at 2500 mg, the highest evaluated dose. Symptom Improvement: Improvements in symptoms were also observed in the majority of patients, with 53% of patients achieving at least a 50% best TSS reduction (TSS50). At Week 24, 32% of patients achieved TSS50, including 29% and 33% of JAK ineligible and JAK R/R/I patients, respectively. Anemia: Rapid and durable anemia improvements were observed in most patients, with anemia response occurring in 60% of evaluable anemic patients, and 52% of patients achieved a major anemia response. Improvements in anemia were observed across patients regardless of prior JAK exposure, including 63% of JAK R/R/I patients and 55% of JAK ineligible patients. Molecular: Consistent reductions in variant allele frequency (VAF) were observed across most patients, regardless of prior JAK exposure and mutation type, with 89% of patients achieving a reduction in whole blood mutCALR VAF (Type 1: 90%, Non-Type 1: 88%), and 81% of patients achieving a ≥25% reduction in mutCALR peripheral blood mononuclear cells (PBMC) from baseline (Type 1: 62%, Non-Type 1: 38%). INCA033989 was generally well-tolerated, with 84% (70/83) of patients remaining on therapy at the time of the data cut off. Treatment emergent adverse events (TEAEs) occurred in 92% (76) of patients, with 27% (22) of patients experiencing Grade ≥3 TEAEs, the most frequent of which were cytopenias. No dose-limiting toxicities were observed, and discontinuations due to TEAEs were limited (n=2).

Combination therapy: INCA033989 (dose range: 70 to 2,500 mg) was evaluated in combination with ruxolitinib in patients with MF who experience a suboptimal response to ruxolitinib monotherapy. INCA033989 demonstrated additive, multi-domain clinical activity in patients when administered in combination with ruxolitinib.

SVR: At Week 24, 55% (11/20) and 30% (6/20) of patients achieved SVR25 and SVR35, respectively. Symptom Improvement: 31% (5/16) of patients achieved TSS50 at Week 24. Anemia: Anemia response occurred in 35% (6/17) of evaluable anemic patients. INCA033989 in combination with ruxolitinib was generally well-tolerated, with 76% (16) of patients remaining on treatment at the time of the data cut off. In the combination arm (n=21), all patients experienced TEAEs. Grade ≥3 TEAEs were reported in 67% (14) of patients, most commonly anemia (33%).

Translational data

Clinical response occurred regardless of mutational complexity with SVR, anemia and molecular responses observed in patients with and without high molecular risk (HMR) mutations. 93% of patients with HMR had a reduction in whole blood mutCALR VAF, as did 88% of those without HMR mutations. A reduction in mutCALR-positive hematopoietic stem and progenitor cells (HSPCs) was also seen, indicating activity at the level of disease-initiating cells. "Patients with CALR-mutated MF have distinct disease biology and often respond poorly to available therapies, underscoring the need for treatments targeting the underlying driver of disease," said Claire Harrison, M.D., Professor of MPNs and Deputy Chief Medical Officer, Guy’s and St. Thomas’ NHS Foundation Trust. "What stands out in these data is that INCA033989 produced rapid and robust spleen, symptom and anemia responses, alongside reductions in mutCALR allele burden regardless of HMR mutations, pointing to activity at the level of the disease-initiating clone."

Results in Patients with Essential Thrombocythemia

In patients with ET, INCA033989 demonstrated rapid, deep and durable hematologic and molecular responses across both Type 1 and non-Type 1 CALR patients, supporting potential for disease modification in a population resistant or intolerant to prior cytoreductive therapy.

Hematologic Response:

Across doses, 70% (80/114) of patients achieved a complete hematologic response (CHR, platelet count ≤400 × 109/L and leukocytes <10 × 109/L) and 87% achieved complete or partial hematologic response (CHR/PHR, platelet count ≤600 × 109/L and leukocytes <10 × 109/L). 81% of patients with Type 1 mutCALR achieved a durable (>12 weeks) CHR at 750 mg and above; and 50% of patients with non–Type 1 mutCALR achieved a durable CHR/PHR at 2500 mg. The median time to onset of durable CHR was 2.1 weeks. Molecular Response and Disease Biology:

≥25% reduction in mutCALR VAF correlated with durable CHR (nominal P<0.0001, n=103). Of the patients who achieved a CHR and had ≥1 post-baseline VAF assessment, 73% achieved ≥25% reduction in VAF. Durable molecular response was observed in both Type 1 and non–Type 1 mutCALR. A reduction in mutCALR megakaryocytes was seen in both Type 1 and non-Type 1 patients treated with INCA033989 INCA033989 was well tolerated with 95% of patients remaining on treatment. The median duration of INCA033989 exposure was 8.1 months (range from 0.59 to 27.0 months). A low incidence of Grade ≥3 adverse events was observed (19%); the most common were neutropenia (4.4%) and lipase increase (3.5%). Grade ≥3 cytopenia TEAEs occurred in 6% (7/114) of patients; no Grade ≥3 thrombocytopenia TEAEs were observed.

“In patients with ET who were resistant to or intolerant of prior cytoreductive therapy, INCA033989 resulted in rapid and durable normalization of platelet counts with accompanying molecular responses, with the majority of patients achieving a CHR," said John Mascarenhas, M.D., Professor of Medicine at the Icahn School of Medicine at Mt. Sinai and Director, Center of Excellence for Blood Cancers and Myeloid Disorders, The Tisch Cancer Institute. "As there are currently no mutation-specific treatments available for patients with ET, this approach is critically important for this high-risk patient population. These results provide a strong foundation for advancing INCA033989 into a registrational Phase 3 study."

In November of 2025, INCA033989 was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with ET harboring a Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive therapy. A Phase 3 study of INCA033989 in mutCALR positive patients with ET who are resistant or intolerant to at least one prior cytoreductive therapy (EXCALIBUR-ET2, NCT07623200) is being initiated in mid-2026.

More information regarding the EHA 2026 Congress can be found on the EHA website: https://ehaweb.org/connect-network/eha2026-congress.

About Myeloproliferative Neoplasms (MPNs) and Mutations in Calreticulin (mutCALR)

Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein folding. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs),1 a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells.2,3 Among two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases.4 In MF, it is estimated that 70-83% of CALR mutations in the U.S. are identified as Type 1, with 15-30% identified as non-Type 1.4,5 There are currently no targeted therapies for CALR mutations.

Incyte is at the forefront of developing novel therapies for patients with mutCALR ET or MF that target only malignant cells, sparing normal cells, including INCA033989, a first-in-class, mutCALR-specific therapy. INCA033989 received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with ET harboring a Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive therapy. A Phase 3 study of INCA033989 in patients with ET with a Type 1 or non-Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive therapy is being initiated (EXCALIBUR-ET2, NCT07623200).

About the INCA33989-101 & INCA33989-102 Trials

The clinical trial program for INCA033989 includes two multicenter, open-label Phase 1 studies, INCA33989-101 (NCT05936359) and INCA33989-102 (NCT06034002). The studies are evaluating the safety, tolerability and efficacy of INCA033989 in ~455 adult (≥18 years old) patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF).

The primary endpoint of the studies is measured by the number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs) and the number of participants with TEAEs leading to dose modification or discontinuation. Secondary endpoints include response rates, mean change of ET total symptom score, percentage of MF patients achieving spleen volume reduction, MF patient anemia response, mean change in disease-related allele burden and various pharmacokinetics measures.

For more information on the studies, please visit: https://clinicaltrials.gov/study/NCT05936359 and https://clinicaltrials.gov/study/NCT06034002.

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the presentation of data for INCA033989; the potential for disease modification and the potential to benefit patients offered by INCA033989; expectations regarding ongoing and future clinical trials, including the timing of such trials; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; the efficacy or safety of Incyte’s products; Incyte’s ability to achieve commercial success for its products, once approved; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; greater than expected expenses, including expenses relating to litigation or strategic activities; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025, and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.

1 Raghavan, M., Wijeyesakere S.J., Peters L.R., Del Cid N. (2013) Calreticulin in the immune system: ins and outs. Trends in Immunology, 34(1):13-21. Link to source (https://www.cell.com/trends/immunology/abstract/S1471-4906(12)00131-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1471490612001317%3Fshowall%3Dtrue)
2 Nangalia J. Massie C.E., Baxter E.J., Nice F.L., et al. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369(25):2391-2405. Link to source (https://www.nejm.org/doi/10.1056/NEJMoa1312542?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov)
3 Klampfl T., Gisslinger, H., Harutyunyan A.S., et al. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. New England Journal of Medicine, 369(25):2379-2390. Link to source (https://www.nejm.org/doi/10.1056/NEJMoa1311347?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov)
4 Salzman G. and Mullally A. (2026) Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis. Blood, 147(12):1267-1277. Link to source (https://doi.org/10.1182/blood.2025028642)
5 Guglielmelli, P., Maccari, C., Sordi, B. et al. Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. Blood Cancer J. 13, 21 (2023). Link to source (https://doi.org/10.1038/s41408-023-00786-x)

Listen to the audio version of this article (generated by AI).

Editor’s note: “Why X Money Could Be Bigger Than PayPal Ever Was” was previously published in May 2026. It has since been updated to include the most relevant information available.

When you think about Elon Musk’s defining business achievements, what comes to mind?

Tesla (TSLA) — the company that pulled off a 20,000% stock run and turned skeptical engineers into reluctant millionaires? SpaceX — the rocket company that went from a laughingstock to a $2-trillion juggernaut and is now the most anticipated IPO in history?

As impressive as those growth stories are, they may not be the endgame… 

Almost entirely outside the focus of mainstream financial media, Elon Musk is executing the most audacious move of his entire career — one he has been plotting for 27 years. It’s a move that targets not a single industry, but the foundation of how money itself flows through the global economy.

He calls it X Money.

Elon Musk’s 27-Year Battle to Reinvent Banking  Back in 1999, Elon Musk — then 28 years old, flush with $22 million from selling his first company — poured nearly everything he had into a single idea: that the entire global financial system could live at a single web address.

Banking. Payments. Investments. Insurance. Loans. All of it. One platform. Instant transactions. No waiting for payments to clear. No middlemen skimming fees at every step.

He called it X.com, and within two months of launch, it had 200,000 users. 

Around the same time, another startup — Peter Thiel’s Confinity — was growing rapidly with its own digital payments product. The two companies were locked in a costly battle for users, burning cash to dominate the emerging online-payments market. In 2000, they merged under the X.com umbrella in an attempt to survive the dot-com crash and consolidate market share. But the merger quickly devolved into an internal civil war over leadership, strategy, and Musk’s vision for the company. 

Then came the coup.

Peter Thiel and his allies called an emergency board meeting while Elon and his new wife were mid-air on a honeymoon flight to Sydney. By the time the plane landed, Musk had been forced out of his own company. His partners hated the name X and changed it to PayPal (PYPL). The dream of a unified financial OS — dead on arrival.

Why Buying Twitter Was Never Really About Social Media  That was 27 years ago.

Elon Musk never forgot — and never stopped wanting to finish what he started.

In 2022, he saw his chance. He bought Twitter for $44 billion. The mainstream media mocked him relentlessly. ‘Classic Musk, overpaying for a failing social media company.’ 

But Musk didn’t buy Twitter because he wanted to own a social media company. He bought Twitter as a distribution layer, with a user base of hundreds of millions of people already using the platform daily.

He renamed it X, partnered with Visa (V) — the financial network that processes more electronic payments than any company in the world — and secured money-transmitter licenses in all 50 states. And he brought X into his broader empire, merging it with the AI firepower of xAI.

Suddenly, everything makes sense. The rebrand. The financial licenses. The Visa deal. The White House executive order directing the Treasury, State Department, HHS, Veterans Affairs, Education, and Homeland Security to modernize electronic payment rails. 

Musk didn’t just build a product. He built the regulatory infrastructure to go with it. In fact, as he’s said: “If done right, X would be half of the global financial system.”

Well, that system is worth $480 trillion. If Musk is right about X Money, it’s more than a startup chasing a billion-dollar market. 

It’s an attempt to transform one of the most deeply embedded systems in the global economy. 

Every Financial Infrastructure Shift Creates New Winners  Every time technology fundamentally changes how money moves, entirely new financial giants emerge alongside it. 

Telegraphs Created Western Union  By the 1850s, telegraph lines were rapidly connecting American cities, allowing information — and eventually money — to move across the country almost instantly. Western Union (WU) quickly realized that the same network transmitting information could also move money — and turned wire transfers into a national business. Western Union was one of the original 11 companies listed on the Dow Transportation Index in 1884. Technology met money. Fortunes were made.

Credit Cards Built Financial Giants  In 1950, Frank McNamara launched the Diners Club card — the world’s first multipurpose charge card. It was designed to allow business travelers to pay at multiple restaurants without carrying cash. The card’s success gave birth to the ‘plastic money’ revolution. American Express (AXP) rode the wave to nearly 10,000% gains. Mastercard (MA) ultimately rose 14,000%. 

The Internet Birthed PayPal  In 1998, PayPal set out to make sending money as easy as sending an email. Within four years, it had 20 million users and went public on Nasdaq. Early investors who got in at the IPO price of $13 saw the stock eventually reach $310 at its peak — a 2,300% gain. Those who bought in the months after the dot-com crash, when the stock briefly traded under $5, did even better.

Now the next chapter is being written. And if history is any guide, the investors who recognize it earliest will be the ones who benefit most.

What X Money Actually Is Most people might hear “X Money” and think it’s just another glorified peer-to-peer payment app, like Venmo or CashApp.

But here’s why that take is fundamentally wrong.

X Money is being built to consolidate payments, banking, investing, and financial identity inside a single platform.  

The physical manifestation of this is a debit card — embedded with a sophisticated microchip — that Musk has already begun mailing to thousands of Americans. That chip contains technology capable of processing encrypted payments, identity verification, and account authentication almost instantaneously. 

But the card is just the consumer-facing layer of this OS. Beneath it sits an integrated financial platform that brings together:

A digital wallet built into an app already used by over 1 billion people worldwide Instant peer-to-peer payments Direct bank account integration Brokerage and investment functionality, allowing users to buy stocks directly inside the app Portfolio management across all financial assets Social Security income, tax payments, paychecks — all managed in one place Yields between 4% and 6% APY — roughly 10x what most Americans earn at traditional banks Musk has been explicit about his ambition here: “If it involves money, it’ll be on our platform. I’m talking about someone’s entire financial life.” 

And lest you think this is science fiction, just look to China. WeChat — which is also called “The Everything App” — launched its banking features in 2013. Within a few years, nearly 1 billion people were using that app to pay for groceries, invest in the market, split restaurant bills, and send money to family. Mobile payments now account for over 80% of all transactions in China. Tencent, WeChat’s parent company, rewarded investors with a 20x return when mobile banking took off.

X Money is the American version of that story. Except Elon Musk has significantly more users, significantly more political tailwind, and significantly more audacity.

The Investment Pattern Investors Keep Missing  This is the pattern investors should be paying closest attention to. 

Elon Musk has a well-documented history of turning early partners and adjacent companies into massive multi-baggers. 

Nvidia (NVDA) was trading at $15 when Jensen Huang personally delivered the first DGX-1 — an “AI supercomputer in a box” — to OpenAI, the then-small startup co-founded by Elon Musk and Sam Altman. That early relationship helped train the models that eventually became ChatGPT — and Nvidia never looked back. It’s now worth nearly $5 trillion and trades at more than $200/share. Early investors made 5,000%-plus. Modine Manufacturing (MOD) partnered with Tesla on battery cooling systems in 2012, when the stock was trading at $5. MOD recently hit an all-time high of $280 — a 5,500% gain. Carpenter Technology (CRS), a 135-year-old metals company, supplied SpaceX with superalloys for Starship. The stock surged 2,000%. In each case, the gains were tied to companies supplying critical infrastructure to a rapidly scaling platform. 

And right now, X Money is creating a new set of partners, suppliers, infrastructure providers, and financial rails that could follow that exact same pattern.

The Bottom Line: X Money Is a Bet on Financial Consolidation  Every major upgrade in the infrastructure of money has created a new class of winners. 

Telegraphs built Western Union. Credit cards built American Express and Mastercard. The internet built PayPal. 

X Money is the next great systematic upgrade. And it is underway right now, as you’re reading these words.

There is a set of stocks that I believe will be the direct beneficiaries of this rollout — companies positioned to provide the financial infrastructure, payment rails, technology integrations, and adjacent services that an endeavor of this scale requires. 

The same way Nvidia rode the AI build-out and Modine rode the Tesla production ramp, there are companies today that will ride the X Money megatrend.

I’ve spent months identifying them, running the same research process I used when I spotted AMD (AMD) before it exploded 13,500%, Palantir (PLTR) before it rose 1,200%, and Shopify (SHOP) before it jumped 1,700%.

I’ve detailed them all in a brand-new special report called How to Make 1,000% From the Bank of Elon.

Here’s everything I know — my complete research, model portfolio, and daily market intelligence — on this very topic.

Markets move faster than ever these days, and yesterday’s winners can quickly become today’s losers. When prices outpace fundamentals, traders often rely on technical indicators and signals to guide their decisions. Momentum indicators like the Relative Strength Index (RSI) don’t have prophetic powers, but they do give clues about where a stock might be headed and how much strength backs the move. Using a combination of indicators together can provide solid evidence that a downtrend is about to break. Or, in the case of these three stocks, that an uptrend is losing momentum.

The tech sector has been one of the most volatile parts of the market over the past few weeks, with the Nasdaq 100 fluctuating by more than 2% in a single day on multiple occasions. While volatile trading sessions make for fun times for day traders, it can be difficult to gauge the market when indices swing by 2% every day. That’s where technical analysis comes into play. Technical indicators utilize recent price data to generate actionable signals about shifts or continuations in momentum. By applying technical analysis, we can make educated predictions about a stock’s future path based on the intensity of buying or selling activity around it.

Get Fortinet alerts:

Each of the following three stocks fits a specific set of criteria. All three have gained 20% or more over the last 12 months, driven by various fundamental and macro factors. However, these stocks are currently showing technical warning signs that investors should carefully examine.

Fortinet: Overbought Peak With Insider Selling WarningFortinet Today

$146.30 +1.24 (+0.85%)

As of 06/12/2026 04:00 PM Eastern

52-Week Range$70.12▼

$150.07P/E Ratio56.49

Price Target$107.77

Fortinet Inc. NASDAQ: FTNT has been the face of the “software isn’t dead” narrative. The $106 billion cybersecurity firm has seen its stock accelerate more than 80% year-to-date (YTD), including more than 70% in the past three months alone.

The software sector seemed to be in the crosshairs of agentic AI, and funds like the iShares Expanded Tech-Software Sector ETF BATS: IGV lost more than 35% of their value between September and April. However, strong earnings from companies like Fortinet showed that AI can complement software platforms rather than wipe them out. Fortinet smashed expectations in Q1 2026, beating both top and bottom line estimates and posting 20% year-over-year (YOY) revenue growth.

Management also raised full-year guidance and repurchased more than $800 million worth of stock. So why is this stock on a “time to sell” list? Because sometimes the most important technical signals aren’t shown on the charts. Insiders have been selling stock at a faster rate over the last two quarters, including a $23 million sale from CEO Ken Xie.

There has been no significant insider buying in the past year, and insider selling at a technical top is often a warning sign. Widening Bollinger Bands indicate that volatile trading has become the norm for FTNT shares, and the Moving Average Convergence Divergence (MACD) indicator has turned bearish following the strong rally. The company’s long-term fundamentals still look promising, but it might be wise to take some short-term profits now.

Amprius: Technical Breakdown Amid Negative CatalystsAmprius Technologies Today

AMPX

Amprius Technologies

$16.30 -0.80 (-4.67%)

As of 06/12/2026 03:59 PM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$3.43▼

$24.23Price Target$21.67

Amprius Technologies Inc. NYSE: AMPX lacks the strong fundamental foundation that Fortinet has, which means its downturn could be much sharper.

The lithium-ion battery producer is beating revenue estimates, and its stock is still up more than 100% YTD, but the rally is faltering amid concerns about the quality of its revenue. A recent report by a short-seller claims that the company inflates its orders and engages in undisclosed transactions with a related party affiliated with Amprius’s CEO.

The company also reported a larger-than-expected loss in its Q1 2026 earnings report on May 6, and insiders have sold $83 million worth of shares over the last three quarters, without a single buy.

AMPX might be heading for the dreaded double top pattern, and other signals suggest that the fun is over. Both the RSI and MACD have been trending down since the middle of March, and now the former has spent most of the last six weeks in bearish territory. AMPX isn’t profitable yet, and short sellers are openly questioning its revenue streams, so it would be wise to avoid this stock or take profits while you can.

AppLovin: Death Cross Overshadows Fundamental StrengthAppLovin Today

$496.77 +18.20 (+3.80%)

As of 06/12/2026 04:00 PM Eastern

52-Week Range$320.00▼

$745.61P/E Ratio42.68

Price Target$669.62

AppLovin Corp. NASDAQ: APP is already down more than 25% YTD, even though it grew revenue by more than 56% in Q1 2026, and remains well-regarded by analysts. But despite a strong fundamental picture, the stock is in the throes of a bear market that’s proving difficult to shake.

It may seem counterintuitive, but APP shares probably won’t reflect the company’s strength until the technical setup improves.

An early-March Death Cross indicated the stock has a long way to go before regaining buying momentum.

The Death Cross sent the stock plunging under the 50-day and 200-day moving averages, where it stayed until late May.

APP shares tried to break out at the end of May, but sellers quickly pushed the share price back below the 200-day moving average, and now it's once again testing the 50-day moving average. With the RSI also below 50, APP shares can remain on your watchlist until they make a significant move above the 50-day moving average.

Should You Invest $1,000 in Fortinet Right Now?Before you consider Fortinet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortinet wasn't on the list.

While Fortinet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AeroVironment To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in AeroVironment between June 25, 2025 and March 10, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AeroVironment, Inc. (“AeroVironment” or the “Company”) (NASDAQ: AVAV) and reminds investors of the July 27, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) AeroVironment understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the SCAR program and the U.S. Space Force’s ongoing efforts to modernize the SCN; (2) accordingly, Defendants overstated AeroVironment’s business and financial prospects; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding AeroVironment’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the AeroVironment class action, go to www.faruqilaw.com/AVAV or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the AeroVironment Securities Class Action Lawsuit:

What is the AeroVironment securities fraud lawsuit about?

The AeroVironment securities fraud lawsuit is a federal securities class action alleging that AeroVironment, Inc. (NASDAQ: AVAV) and its executives made false and misleading statements to investors by concealing that the Company faced imminent competition for its SCAR program contracts and overstating its business and financial prospects. As the truth emerged through a series of disclosures — including a U.S. government stop work order on January 20, 2026, a Space Force announcement that it was reopening the SCAR program on March 2, 2026, and AeroVironment's disclosure of a $151.3 million goodwill impairment and contract termination on March 10, 2026 — AVAV's stock price dropped sharply, causing significant losses for investors.

Who may be eligible to participate in the lawsuit?

Investors who purchased or acquired AeroVironment (AVAV) stock between June 25, 2025 and March 10, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the AeroVironment securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former AeroVironment employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff in the AeroVironment class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any AeroVironment investor who purchased AVAV stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 27, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased AeroVironment stock during the Class Period?

Investors who purchased AeroVironment (AVAV) stock between June 25, 2025 and March 10, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the AeroVironment securities class action is July 27, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/AVAV for more information.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased AeroVironment securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f60c456-51b6-4096-a862-d5d3beda6cc5

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Calix To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Calix between January 28, 2026 and April 21, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Calix, Inc. (“Calix” or the “Company”) (NYSE: CALX) and reminds investors of the July 27, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company's first quarter margins had significantly benefited from advanced purchasing of memory components; (2) that the Company's advanced supply of memory components was dwindling; (3) that, as a result, the Company was experiencing negative margin pressure as it was forced to purchase memory components at rising market prices; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's margins, business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On April 21, 2026, Calix reported results for the first quarter of 2026 earnings, including that "Non-GAAP gross margin was 57.2%, down 80 basis points sequentially." Further, the Company reported "gross margin guidance for the second quarter of 2026 is between 54.25% and 57.25%" and "[f]or the year, we expect our non-GAAP gross margin to decline between 50 and 150 basis points."

In the accompanying earnings call, the Company’s CFO stated "advanced purchasing had allowed us to avoid higher memory component costs during the first quarter. However, that advanced supply has run its course, and we now face market prices."

On this news, Calix's stock price fell $6.93, or 13.98% to close at $42.65 per share on April 22, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Calix’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Calix class action, go to www.faruqilaw.com/CALX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Calix Securities Class Action Lawsuit:

What is the Calix securities fraud lawsuit about?
The Calix securities fraud lawsuit is a federal securities class action alleging that Calix, Inc. (NYSE: CALX) and its executives made false and misleading statements to investors by concealing that the Company's strong first quarter margins were artificially inflated by advanced purchasing of memory components, that its advanced supply of those components was dwindling, and that it would soon be forced to purchase memory components at rising market prices — creating significant negative margin pressure. As the truth emerged on April 21, 2026, when Calix reported Q1 2026 results and its CFO disclosed that "advanced supply has run its course" and the Company would "now face market prices," CALX's stock price fell $6.93 per share, or 13.98%, causing significant losses for investors.

Who may be eligible to participate in the Calix class action lawsuit?
Investors who purchased or acquired Calix (CALX) stock between January 28, 2026 and April 21, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the Calix securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Calix employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Calix lawsuit?
A lead plaintiff in the Calix class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any Calix investor who purchased CALX stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 27, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Calix stock during the Class Period?
Investors who purchased Calix (CALX) stock between January 28, 2026 and April 21, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Calix securities class action is July 27, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/CALX for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f60c456-51b6-4096-a862-d5d3beda6cc5

16.68K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of AAOI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

London, June 13, 2026 (GLOBE NEWSWIRE) --

The stuff that makes AI work, called AI infrastructure, is one of the fastest-growing parts of the digital economy worldwide. Fortune Business Insights says this market could jump from about $75 billion in 2026 to nearly $500 billion by 2034. This really shows how quickly AI, GPU computing, data centers, and cloud AI systems are expanding.

Meanwhile, data centers worldwide are also getting much busier. JLL's report for 2026 predicts that global data center capacity could hit 200 gigawatts by 2030. They expect this whole area to almost double between 2025 and 2030 because huge cloud services are expanding and more AI needs more power.

All this fast growth is opening up a new way to invest: in AI computing power itself.

Instead of just putting money into AI stocks, tokens, or chip companies, more people are now looking at the actual systems that power AI. This includes things like GPU power, AI data centers, renting cloud GPUs, leasing computing power, and new ways to earn money from digital infrastructure without much effort.

To help people get involved in this growing market, AI GPU Rental has launched its 2026 AI Computing Power Investment Contracts. These offer people worldwide an easy way to join AI infrastructure projects by leasing computing power for short periods. New users who qualify can also get up to $128 in trial credits as part of this offer.

Investing in AI Infrastructure Through Computing Power Contracts

The systems that run AI need a huge amount of computing power. Every AI model, automated system, cloud app, data processing system, and business AI tool needs GPUs to work.

But building your own AI infrastructure is very costly. Buying GPU servers, ensuring enough electricity, handling cooling, maintaining hardware, and running data centers all need a lot of money and technical know-how.

AI GPU Rental offers a simpler way to do this.

Users don't need to buy GPU machines or run data centers. Instead, they can get involved with AI computing power contracts through the platform. Each contract is for a short period of AI computing power, and you'll see how much it costs to start, how long it lasts, and an estimated daily and total return before you commit.

This lets people get into the AI infrastructure investment market through a set contract system instead of owning hardware outright. If you're looking for ways to earn AI passive income, the platform gives you a contract-based way to see how much you might make from renting cloud GPUs and leasing AI computing power.

How Users Can Participate and Earn Passive Income

The process is simple.

Users go to the AI GPU Rental platform, look at the available AI computing power contracts, pick a plan that fits their budget and how long they want to commit, and then activate it.

After activation, the platform puts the chosen amount into the AI computing power leasing project. During the contract, users can check the estimated daily earnings shown on the platform. At the end of the contract, users get the total amount shown for the end of the term, following the platform's rules.

This system is for people who want a way to get involved with AI infrastructure investment, cloud GPU rental, GPU rental income, AI passive income, and AI computing power opportunities without dealing with the technical details.

2026 AI Computing Power Investment Contract Options

AI GPU Rental currently offers several short-term computing power contracts, designed for different investment levels.

The Starter Plan is for people who want to try out AI computing investment with a smaller starting amount and just for one day.

The A15 Compute and A2 Cluster contracts offer bigger options for those who want more AI computing power.

For people looking for even more AI infrastructure, GPU Node and Hyd Compute offer higher-capacity contracts that show bigger estimated returns at the end.

Each plan is set up for short periods, letting users see how much passive income they might make from leasing AI computing power, all without buying or looking after hardware.

Up to $128 in Trial Credits for New Users

As part of its 2026 offer, AI GPU Rental is giving qualified new users up to $128 in trial credits.

These trial credits are meant to help new users check out the platform, look at the available AI computing power contracts, and get a feel for how investing in AI infrastructure works before they choose a bigger plan.

If you're looking for ideas for AI passive income, AI infrastructure investment, ways to earn from GPU rentals, or cloud GPU investment platforms, this offer makes it easier to get started.

Why AI Computing Power Investment Is Attracting Attention

The AI boom is making one of the most important digital resources much more in demand: computing power.

As more companies create AI tools, train models, set up automated systems, and handle huge amounts of data, the need for GPU infrastructure will likely keep going up. This is why renting cloud GPUs and having enough AI data center space are getting a lot of attention in the market.

AI GPU Rental focuses its platform on this trend by letting users get involved with AI computing power contracts without buying hardware themselves.

Here are some advantages:

Users can get into AI infrastructure investment without buying GPU machines.Users can see how much passive income they might earn from leasing AI computing power.Users don't need to manage electricity, cooling, or hardware upkeep.Short-term contracts offer flexible choices for getting involved.There are different starting amounts for different users.You can see daily and end-of-term estimates before you pick a contract.New users might get up to $128 in trial credits during this offer. AI Passive Income Becomes a 2026 Market Theme

Artificial intelligence is shifting from just software to the underlying systems. The next phase of AI growth isn't just about the apps, but also about the computing power needed to make them work.

This change is making investments in AI infrastructure, AI computing power contracts, cloud GPU rental, GPU rental income, and AI passive income opportunities more noticeable in the market.

AI GPU Rental's 2026 computing power investment offer is meant to give people a direct way to join this trend with short-term contract options.

For beginners, the Starter Plan offers a smaller starting option. For those looking to invest more, A15 Compute, A2 Cluster, GPU Node, and Hyd Compute provide bigger capacity choices.

As the demand for AI infrastructure keeps growing, AI GPU Rental wants to be a platform for people who want to get involved in the AI computing power economy and see if they can earn passive income through flexible, contract-based investments.

About AI GPU Rental

AI GPU Rental is a platform for AI infrastructure and cloud GPU leasing that deals with short-term contracts for investing in AI computing power. It lets users take part in AI computing lease projects without having to buy physical GPU hardware or deal with the technical setup.

The platform's 2026 offer includes several AI computing investment contracts and an offer for qualified new users to get up to $128 in trial credits.

All contract figures, daily estimates, and end-of-term estimates shown here are just examples for this offer. What actually happens for users can change based on their account, platform rules, how the market is doing, if computing resources are available, and the official contract details.

MEDIA CONTACT

Contact: David Pawson
Official website：https://www.aigpurental.com/
Email: [email protected]

Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In POET Technologies To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in POET Technologies between April 1, 2026 and 08:57 AM EST on April 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - June 13, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against POET Technologies, Inc. ("POET Technologies" or the "Company") (NASDAQ: POET) and reminds investors of the June 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Watch our latest video highlighting the key allegations: https://youtu.be/zdxRFbToG4A

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) POET Technologies misrepresented its tax status due to it likely being deemed a passive foreign investment company (or "PFIC") under U.S. tax laws which, if not properly reported by each U.S. stockholder, would have negative tax implications for those U.S. stockholders; (2) the foregoing tax issue would, if discovered, make POET Technologies a less attractive investment than it would otherwise be, thus threatening POET Technologies' valuation; (3) Defendant Thomas Mika, despite affirming that he was not violating a non-disclosure agreement, in fact violated a business agreement by speaking about POET Technologies' business agreements in a public interview, thus endangering POET Technologies' business prospects, and (4) as a result, defendants' statements about POET Technologies' business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On April 27, 2026, Investing.com published an article entitled "POET Technologies stock tumbles after losing Marvell orders." The article stated that POET Technologies stock fell "after the company disclosed the cancellation of all purchase orders from Celestial AI, now owned by Marvell Semiconductor Inc. Marvell provided written notice on April 23, 2026, canceling all purchase orders, including those for initial production units first announced by POET Technologies in a press release on April 25, 2023. Marvell cited the company's disclosures of information related to the purchase orders and shipping details as violations of confidentiality obligations."

Following this news, POET Technologies' stock dropped more than 45% during intraday trading on April 27, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding POET Technologies' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the POET Technologies class action, go to www.faruqilaw.com/POET or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the POET Technologies, Inc. Securities Class Action Lawsuit:

What is the POET Technologies securities fraud lawsuit about?

The POET Technologies securities fraud lawsuit is a federal securities class action alleging that POET Technologies, Inc. (NASDAQ: POET) and its executives made false and misleading statements to investors by misrepresenting the Company's tax status - concealing that it likely qualified as a passive foreign investment company (PFIC) under U.S. tax law, which carries negative tax implications for U.S. stockholders - and by having a Company executive publicly discuss confidential business agreements in violation of a business agreement with a key customer. As the truth emerged on April 27, 2026, when it was reported that Marvell Semiconductor had canceled all purchase orders from POET Technologies, citing the Company's unauthorized disclosures of confidential order and shipping details as violations of its confidentiality obligations, POET's stock dropped more than 45% during intraday trading, causing significant losses for investors.

Who may be eligible to participate in the POET Technologies class action lawsuit?

Investors who purchased or acquired POET Technologies, Inc. (POET) securities between April 1, 2026 and 8:57 AM EST on April 27, 2026 - the Class Period - and suffered financial losses may be eligible to participate in the POET Technologies securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former POET Technologies employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the POET Technologies lawsuit?

A lead plaintiff in the POET Technologies class action is a court-appointed investor - typically the one with the largest financial interest in the case - who directs and oversees the litigation on behalf of all class members. Any POET Technologies investor who purchased POET securities during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is June 29, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased POET Technologies stock during the Class Period?

Investors who purchased POET Technologies, Inc. (POET) securities between April 1, 2026 and April 27, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the POET Technologies securities class action is June 29, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/POET for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301304

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

SpaceX (NASDAQ: SPCX) just went public in the largest IPO of all time, raising $75 billion at a valuation of nearly $1.8 trillion. Many investors are excited to finally own a piece of the Starlink satellite internet business, SpaceX's dominant rocket launch business, and the high-potential xAI artificial intelligence business.

However, the story here goes beyond how SpaceX stock will perform as a publicly traded company. It's important for investors to keep in mind that SpaceX just raised $75 billion in fresh capital, and with big growth ambitions, the company will deploy it into AI computing hardware, rocket and satellite parts, and more. And there are some publicly traded companies that could be big winners now that such a big customer has much deeper pockets.

With that in mind, here are five companies in particular that could be big beneficiaries of SpaceX's IPO windfall for years to come.

Image source: Getty Images.

5 Companies that could make billions now that SpaceX is public To be clear, there are more than just five. SpaceX buys components from dozens of companies, and many others are likely to get secondary tailwinds from the IPO. But here are five in particular that investors might want to take a closer look at.

1. Alphabet Alphabet (GOOG +0.44%)(GOOGL +0.53%) could be a big winner from the SpaceX IPO, but not because SpaceX is a major customer. Alphabet made a $900 million investment in SpaceX in 2015, when SpaceX had a $12 billion valuation. At the IPO valuation, Alphabet's stake is worth about $150 billion. That's already an incredible return, but if SpaceX's stock were to rise post-IPO, it could become a serious needle-mover for the Google parent company.

2. Nvidia You've probably heard about SpaceX's deals to provide compute infrastructure to Anthropic and Google, which will require SpaceX to continue purchasing hundreds of thousands of GPUs and other AI computing components. And I wouldn't be surprised to see further compute deals announced, creating an excellent recurring revenue stream for SpaceX. Nvidia (NVDA +0.15%) is likely the most direct beneficiary of SpaceX's deeper pockets post-IPO.

3. Moog Now we're starting to dig a little deeper. Moog (MOGA 2.55%) is the leader in precision motion control systems for the aviation, space, and defense industries. The company provides essential components for many satellites, and once Starship improves SpaceX's launch economics, the volume of new satellite deployments could increase rapidly.

4. Kratos Defense & Security Kratos Defense & Security (KTOS 1.75%) is best known for its unmanned aerial vehicles (drones), but it also offers the only commercially available satellite ground system, OpenSpace. Even if Kratos doesn't get a direct SpaceX contract, it is a clear beneficiary as the commercial satellite economy accelerates.

5. Intel To say that Intel (INTC +6.49%) has been a big winner recently would be an understatement. The company has benefited from an investment from the U.S. government and partnerships with Nvidia, Apple (AAPL 1.52%), and other tech giants. Investors have been handsomely rewarded, with the stock up about 500% over the past year alone. However, it's also worth noting that Intel has a close relationship with both SpaceX and Tesla (TSLA +1.65%) as a key Terafab partner. Specifically, Terafab will use Intel's next-generation fabrication technology, and the capital SpaceX raised in its IPO could be a major source of funding to get the Terafab project going.

The bottom line As mentioned, there could be plenty of winners from the SpaceX IPO. But these are five companies that should be major beneficiaries of SpaceX's massive infusion of capital for years to come, and they could be worth a look for patient investors.

Matt Frankel, CFP® has positions in Kratos Defense & Security Solutions. The Motley Fool has positions in and recommends Alphabet, Apple, Intel, Kratos Defense & Security Solutions, Moog, Nvidia, and Tesla. The Motley Fool has a disclosure policy.

HomePersonal FinanceReal Estate2025 set an all-time high for first-time buyers who used financial assets to buy a home or fund a down payment, according to the National Association of RealtorsPublished: June 13, 2026 at 9:00 a.m. ET

The SpaceX IPO could change the game on high-end real estate in Texas — and elsewhere. Photo: Getty Images)The SpaceX IPO is creating a whole new round of deep-pocketed home buyers — and deepening the gulf between high-end housing markets and everyday real estate.

Austin, Texas-based real-estate agent Matt Holm is already helping some SpaceX employees with their home search. Friday — when a record-breaking initial public offering kicked off trading of SpaceX’s stock SPCX — marked “a pretty good one-day bump to millionaires and billionaires in one town,” said Holm, team lead of the Holm Team with Compass Real Estate COMP.

Alphabet (GOOG +0.44%) (GOOGL +0.53%) has gone on an impressive run over the past year. It's up around 100%, which is incredible considering that Alphabet is now the second-largest company in the world. However, after a run-up like that in a relatively short time frame, investors may be asking themselves if Alphabet stock still has room for more upside in the future.

Let's take a look at Alphabet's rise and future, and see if there's more in store.

Image source: Getty Images.

Alphabet's valuation is reaching new heights Alphabet is better known as Google's parent company. A year ago, the Google Search engine was largely presumed to be obsolete and soon to be replaced by generative AI.

However, that hasn't happened. Instead, Google has masterfully integrated AI into the traditional Google Search engine to give users an AI overview for many of the searches they conduct. This is the most exposure that a large majority of the population will have to AI, and Google being the face of it is good for its future.

Despite its legacy status, Google Search still knows how to get it done from a growth standpoint, with revenue rising 19% year over year during Q1. That places it among the best-performing Alphabet segments, but it isn't even touching Google Cloud.

Google Cloud is Alphabet's cloud computing division, and its revenue grew at an impressive 63% pace in Q1. This growth rate highlights two things. First, there is a massive demand for Google Cloud's servers and AI computing capabilities. Second, Alphabet is making a ton of money from selling its in-house custom AI chips to external customers. Those sales are included in the Google Cloud growth rate, giving it a further boost.

Today's Change

(

0.53

%) $

1.90

Current Price

$

359.67

All of this adds up to a company that's posting solid growth for its size and maturity, with revenue rising 22% year over year and operating income increasing 30%. There's nothing to gripe about regarding Alphabet's core business, but after the stock has doubled in the past year, investors need to look at valuation.

Alphabet's shares trade at about 25 times forward earnings, which isn't necessarily expensive for a big tech company. However, it's not cheap either. The S&P 500 trades for 22.2 times forward earnings, which indicates that Alphabet trades at a premium to the market. However, with Alphabet growing faster than the market, this slight premium is likely worth it.

Alphabet's stock was clearly undervalued a year ago, but that's no longer the case after a meteoric rise. While it's not a screaming deal right now, it's also not a bad investment and will likely outperform the market moving forward if it can keep up its high, double-digit growth rates.

So far this year, Nvidia (NVDA +0.15%) stock has gained 8% -- placing it slightly above the returns in the S&P 500 and nominally trailing those seen in the Nasdaq.

From a valuation perspective, the world's most valuable company boasts a forward price-to-earnings (P/E) ratio of about 22. Moreover, Nvidia's forward P/E has spent much of 2026 locked in a narrow corridor between roughly 18 and 25.

This steadiness raises two questions: When was the last time investors saw Nvidia's forward multiple behave this way and what happened next?

Image source: Nvidia.

Nvidia's valuation profile echoes its pre-AI boom Per the chart below, investors can see that Nvidia's forward P/E has not traded inside a comparable, compressed band since before the artificial intelligence (AI) revolution. Prior to the outburst of generative AI models back in late 2022, the market largely viewed Nvidia as a company primarily focused on graphics and gaming with a data center services side hustle.

NVDA PE Ratio (Forward) data by YCharts.

Once ChatGPT, Anthropic's Claude, and a handful of other frontier models arrived, demand for accelerated computing exploded. As it turns out, Nvidia's first-mover advantage in designing graphics processing units (GPUs) was uniquely positioned for this moment. Hence, the company's revenue and earnings rose dramatically virtually overnight. Subsequently, Nvidia's forward earnings valuation multiple broke out and spent the next few years oscillating at levels frequently above 40.

The current range represents a reversion to a pre-AI boom rhythm. Against this backdrop, the current sideways trading seen in Nvidia is the first real extended stretch of valuation stability since the world began pricing the company as the indispensable king of AI infrastructure build-outs.

Don't let valuation distract you from Nvidia's guidance Nvidia's valuation profile looks even more striking when set against the company's actual operating momentum. During the fiscal 2027 first quarter (ended April 26,2026), revenue from Nvidia's data center segment surged 92% year over year, reaching $75 billion. Management forecasted total revenue to be $91 billion next quarter, plus or minus 2%. This represents an acceleration quarter over quarter and a staggering 95% year-over-year growth.

To me, a forward earnings multiple stuck around 22 does not necessarily signal skepticism about Nvidia's near-term earnings power. Instead, I think it reflects a situation whereby the market has already baked in meaningful growth and is no longer willing to pay the premium multiples witnessed throughout 2023 to 2025.

Today's Change

(

0.15

%) $

0.30

Current Price

$

205.18

In other words, range-bound valuation multiples can be normal when investors simply expect continued strong top- and bottom-line expansion. These dynamics are actually quite common for mature, high-growth technology platforms.

Nvidia is positioned for another leg of valuation expansion After Nvidia's forward P/E dropped sharply to about 18 earlier this year, the multiple has more recently stabilized and begun to edge modestly higher within a tight range. This could suggest that early stages of valuation expansion are in the works. Perhaps the clearest reason why is Nvidia's growing number of strategic partnerships. These are the clearest catalysts for Nvidia's next leg up.

The company has invested billions of dollars in Nokia, Coherent, Lumentum, and Marvell Technology to fortify high-speed optical interconnects and advanced networking. These technologies are becoming increasingly important as hyperscalers allocate capital expenditure (capex) beyond GPU procurement and build more sophisticated infrastructure stacks within AI factories. Moreover, these relationships unlock numerous opportunities for Nvidia beyond data centers -- opening the door to scalable edge computing, robotics platforms, and autonomous vehicle systems.

These moves quietly broaden Nvidia's total addressable market (TAM) beyond chips. I think the company has started laying the groundwork to justify higher valuation multiples once execution catches up with these new opportunities. History suggests that if Nvidia's strong guidance is delivered, the current range-bound phase should turn out to be nothing more than a temporary consolidation before the next chapter of significant valuation rerating unfolds.

Exclusive

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Under CEO Josh D'Amaro, Disney has empowered employees to use AI tools like Claude. Samuel Boivin/NurPhoto via Getty Images; Aurore Marechal/Getty Images Disney is encouraging streaming staffers to embrace AI while warning against wasteful token usage.

Streaming leaders at the Mouse House have recently been pushing employees to boost their velocity and productivity by using AI, two senior tech employees told Business Insider.

"The No. 1 thing is to increase velocity," or the pace of output, a high-level, AI-focused employee said.

However, Disney doesn't want its employees to be "tokenmaxxing," Andre Rohe, Disney's EVP of product engineering, said in a Wednesday meeting, according to two tech staffers in attendance. "Tokenmaxxing" refers to maximizing AI token usage, regardless of its impact on productivity.

One software engineer shared their three main takeaways from what Disney streaming leaders said on the call:

AI token tracking is meant to identify inefficient usageDisney wants to increase velocity when shipping features or delivering codeDisney is focused on code quality and product resiliency, not just speed, and hopes to minimize AI-coded products that fail after their releaseDisney has warmed to AI in the last year, providing employees with coding tools like Claude and Cursor while creating an AI Adoption Dashboard for staffers to track token usage. Some managers have sent check-in messages to software engineers who don't use AI.

Disney has also made clear that employees should be intentional about their AI usage. For example, a person familiar with the company's strategy said the AI dashboard isn't meant to incentivize high usage but rather to help staffers use AI tools efficiently and effectively.

Other major US companies, including Microsoft, are trying to limit unchecked AI token usage. Microsoft CEO Satya Nadella recently called tokenmaxxing "addictive." Firms are realizing that burning through AI tokens can be wasteful and may not incentivize the right projects.

One of Disney's Hollywood rivals, Paramount Skydance, informed tech staffers on Wednesday that it would implement "per-user monthly spend limits" on AI tokens. A Paramount exec said the cap would have a "high limit," though.

Out with the OpenAI deal, in with agentic armies and AI affectionDisney surprised the media industry by inking a billion-dollar deal with OpenAI in December that would have licensed its iconic characters to the now-defunct Sora AI video app, while opening the door to put AI-generated videos on Disney+.

The Mouse House got a shock of its own in March when OpenAI canceled its Disney deal and shut down Sora, less than a week into Disney CEO Josh D'Amaro's tenure.

While D'Amaro hasn't struck a major AI deal since its OpenAI arrangement fell apart, Disney spoke with "more than a dozen partners" about ways to implement AI, The Wall Street Journal reported in March.

Disney isn't sitting on its hands and waiting for an AI partner. Its top software engineers are using armies of AI agents to knock out coding projects, allowing them to accomplish far more than they could on their own.

Jason Cox, Disney's executive director of AI research and development and engineering, created an AI assistant he calls his "son" and said, in blog posts, that it had captured his "affection." It's unclear if Cox uses his AI chatbot for his work at Disney.

Read next

James Faris You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Media Exclusive Disney More AI OpenAI

Despite soaring energy prices and geopolitical tension, travel demand remains strong as the summer kicks off. The U.S. Travel Association projects inflation-adjusted travel spending to grow 1% in 2026 and 3% in 2027, with international travel in the U.S. rebounding due to the World Cup. Earlier this month, CoStar and Tourism Economics upgraded their U.S. RevPAR (revenue per available room) forecast to 2.8% year-over-year (YOY) following a 4.0% figure in Q1 2026, the highest quarterly RevPAR number on record.

Naturally, the travel sector is booming, right? Not so fast, my friend. Hotel stocks are making new highs, but airline, cruise line, and other travel stocks are lagging both the broader market and their hotel industry peers. Why is one subsector winning big while the rest of the industry lags? The answer, of course, lies in the Strait of Hormuz.

Get Marriott International alerts:

Oil Is the Travel Sector’s Macro Sorting MechanismOil prices have been elevated above $90 per barrel since early March when Iran closed the Strait of Hormuz. High energy prices have squeezed consumers, yet travel demand remains firm. However, oil has become a sorting mechanism in the travel industry, and the market is re-rating the sector based on fuel exposure in earnings, not raw demand.

Airlines: Fuel is one of the three biggest cost line items for any airline, and consistently high jet fuel prices are cutting into airline profits. The U.S. Global Jets ETF NYSE: JETS is down more than 2% year-to-date (YTD), and the best-performing airline stock, Delta Air Lines Inc. NYSE: DAL, is also the most hedged since it owns a refinery.

Cruiselines: Despite record bookings, the cruise line industry’s earnings are also facing pressure from the oil shock. Norwegian Cruise Line Holdings Ltd. NYSE: NCLH already lowered its full-year 2026 EPS outlook during its Q1 2026 report last month. And the only oil-hedged cruise line, Royal Caribbean Cruises NYSE: RCL, is still down more than 3% YTD.

Online Travel Agencies (OTAs): OTAs aren’t insulated from the oil shock despite having no fuel costs. Tapped-out vacationers are eschewing international travel for cheaper domestic trips that reduce overall spend and slash OTA fee revenue. Airlines could also offset fuel cost increases by slashing commissions paid to OTAs for their listings. Booking Holdings Inc. NASDAQ: BKNG, the largest publicly-traded OTA, is down more than 25% YTD.

It’s not hard to see why hotels have outperformed. Hotels are best positioned to monetize travel demand because they don’t have to cover fuel costs. And some of the industry leaders aren’t even paying the mortgage on the real estate anymore.

2 Hotel Stocks Setting New Highs This SummerThe three hotel stocks listed here all have a common theme: a franchise business model. Under this model, a hotel franchisee bears all cyclical risks, including mortgage costs, labor, depreciation, insurance, and utilities. The brand collects a percentage of gross room revenue and other fees, and allows the operator to use their name and access their booking and loyalty engines. A capital-light system with recurring revenue is ideal for a macro shock environment, which is why these stocks have soared to new highs this year.

Marriott: Fee Machine Firing on All CylindersMarriott International Today

MAR

Marriott International

$402.54 +5.65 (+1.42%)

As of 06/12/2026 04:00 PM Eastern

52-Week Range$253.55▼

$403.25Dividend Yield0.73%

P/E Ratio42.24

Price Target$382.07

Non-RevPAR revenue streams are what set Marriott International Inc. NYSE: MAR apart from its peers.

Card fees were up 37% YOY in Q1 2026, and management boosted full-year gross fee guidance to a range of $5.93 billion to $5.99 billion.

The pipeline is also robust; a record 618,000 rooms, 43% of which are already under construction. Q2 RevPAR guidance was also boosted to a top range of 2.5%.

MAR shares are also enjoying strong technical momentum. The 50-day moving average has provided support for nearly a year, and the Moving Average Convergence Divergence (MACD) indicator is signaling a bullish momentum uptick. The fundamentals and technicals confirm the same story, and that’s more upside ahead.

Hilton: The Hotel Industry’s Purest CompounderHilton Worldwide Today

HLT

Hilton Worldwide

$346.17 +4.31 (+1.26%)

As of 06/12/2026 03:59 PM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$241.45▼

$349.03Dividend Yield0.17%

P/E Ratio52.85

Price Target$348.55

Net unit growth is the catalyst for Hilton Worldwide Holdings Inc. NYSE: HLT. The company reported 131 new hotel openings during its Q1 2026 earnings release, with industry-leading net unit growth of 6.3%.

Hilton is targeting 6-7% unit growth over the rest of the year, and it is confident enough in this projection to raise RevPAR growth despite Middle East headwinds. System-wide RevPAR of 3.6% outperformed expectations, and a record 527,000 rooms are currently in the pipeline.

HLT shares have traded flat since the start of April, but remain up more than 15% YTD, and there’s evidence that the next leg of the rally is imminent. Support remains strong along the 50-day moving average, and the Relative Strength Index (RSI) has now pushed back into bullish territory.

The stock trades at a premium multiple of 37 times forward earnings, but the growth rate and capital returns ($3.5 billion in buybacks and dividends scheduled for 2026) command attention.

Should You Invest $1,000 in Marriott International Right Now?Before you consider Marriott International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Marriott International wasn't on the list.

While Marriott International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Cult stocks attract acquisition speculation the way magnets attract iron filings. A loyal retail base, a strategic asset, and a richly debated future are exactly the ingredients buyers and analysts love to game out. The exercise below is structural in nature. None of the three names here has a confirmed or reported deal in the works, and most acquisition speculation never results in a transaction. The ranking weighs three verifiable factors: ownership and control structure, strategic fit for plausible acquirers, and size or valuation. We count down from least to most acquirable.

3. Reddit: Too Big, Too Controlled, Too Expensive Reddit (NYSE: RDDT | RDDT Price Prediction) is the least likely candidate on this list. The market cap is roughly $33.4 billion, and the business is firing on all cylinders. Q1 FY26 revenue grew 69.1% year over year to $663.41 million, with EPS of $1.01 versus $0.56 expected and daily uniques up 17% to 126.8 million. Net income margin expanded from 6.7% to 30.7%.

Hypergrowth like that signals no distressed sale. Reddit carries a dual-class share structure with founder Steve Huffman and Advance Publications holding outsized voting power, a classic takeover defense. Add antitrust scrutiny shadowing any big-tech bidder for a leading social-data property, plus a freshly authorized $1.0 billion buyback, and the math becomes difficult. The analyst consensus price target is $224.92, with forward earnings at 38x. A buyer would need to pay a premium on top of an already premium multiple. Strategic for AI data licensing? Absolutely. Realistically acquirable in the next 12 months? Not on these terms.

2. Roku: The Strategic Sweet Spot Roku (NASDAQ: ROKU) has been the subject of takeout chatter for years, and the structural case is the cleanest of the three. Market cap of about $18.0 billion is large but digestible for any mega-cap streamer, retailer, or ad-tech buyer. Q1 FY26 revenue rose 22.4% to $1.25 billion, platform revenue jumped 28%, and EPS of $0.57 beat the $0.35 estimate. FY25 was the company’s first profitable full year since IPO.

The strategic case writes itself: 100 million streaming households globally, The Roku Channel commanding 6.3% of all U.S. TV streaming, and first-party CTV ad data that any walled-garden buyer would covet. Founder Anthony Wood executed sizeable Class B-to-Class A conversions totaling 150,000 shares across April and May 2026, an unusual pattern that reduces founder voting concentration. Institutional ownership is high at 88.5%, meaning the float is widely held. Roku is expensive, with forward earnings at 52x, but the asset is unique and increasingly rare.

1. SoundHound AI: The Tuck-In Profile SoundHound AI (NASDAQ: SOUN) tops this structural ranking. Market cap of about $3.0 billion is by far the smallest, the kind of tuck-in size that fits comfortably inside any large-cap technology or automotive-tech acquirer. Q1 FY26 revenue grew 52% year over year to $44.20 million, with organic auto and IoT AI up 88%, marking six consecutive EPS beats. The customer roster reads like a strategic-buyer wish list: Stellantis, Panda Express, IHOP, Jersey Mike’s, Casey’s, BNP Paribas, Walmart ONN TV, plus a Korean OEM and an Italian sportscar brand.

Shares are down 29.4% year to date and 25.7% over the past year, lowering entry cost for any buyer evaluating voice and agentic AI capability at scale. CEO Keyvan Mohajer noted SoundHound “started the year strong with our top line growing 52% … incredible demand across all pillars.” The complicating factor: SoundHound is mid-acquisition, having announced a deal for LivePerson expected to close in H2 2026, with a combined $500 million revenue opportunity. An active acquirer is harder to acquire near-term, but once the LivePerson integration is in motion, SoundHound becomes a cleaner target. Small cap, strategic AI asset, depressed price, and real enterprise traction.

What the Ranking Says Structural acquirability is about the underlying mechanics. Reddit’s control structure and valuation make it the hardest to move. Roku occupies the strategic sweet spot, where size and strategic fit converge. SoundHound carries the cleanest tuck-in profile, even with its own deal in flight. None of these companies has a reported buyer, and structural likelihood is not the same as a coming transaction. What investors can watch is the next layer of evidence: insider behavior, integration milestones at SoundHound, and how Roku’s first-party data story develops as the CTV ad market consolidates.

watch now

Drugmakers are only months into introducing GLP-1 pills and navigating huge changes in how patients pay for weight-loss drugs.

Even so, they're already outlining their visions for the future of obesity drugs.

At the American Diabetes Association's Scientific Sessions in New Orleans last week, drugmakers pitched doctors and investors on the idea of new shots and pills, drugs that can be taken less frequently, and new treatments beyond GLP-1s that could come with fewer side effects. The attendees debated where all these new treatments might fit in, especially with Eli Lilly currently dominating the market for shots and impressing attendees with data from its experimental triple-acting drug retatrutide that produced the most weight loss seen yet.

Lilly and rival Novo Nordisk showcased new GLP-1 pills they each introduced earlier this year. Both companies made the case that oral options are bringing more people into the market for weight loss drugs, with Novo touting that prescriptions of its Wegovy pill reached more than 3 million just five months into the launch.

Behind the two market leaders are a wave of new entrants hoping to get into the massive market in the coming years.

Structure Therapeutics and AstraZeneca each shared mid-stage data from their respective GLP-1 pills. Should those oral drugs succeed in Phase 3 trials, they would likely come to the market around 2029, three years behind Lilly, which introduced its small molecule pill Foundayo earlier this year (the Wegovy pill is an oral peptide).

Structure Therapeutics CEO Ray Stevens thinks there will still be plenty of room in the market by then.

"Who wins at the end of the day with competition? Patients, and that's really what this is all about," Stevens said, adding that being the second small molecule drug will be important. "We're really pushing hard to get into that second position behind orforglipron, now Foundayo."

Pfizer also unveiled mid-stage data from a shot it gained through its $10 billion acquisition of Metsera. The drug showed the potential to be given monthly, which Pfizer thinks would be more convenient than the currently weekly shots. Another drugmaker, Amgen, is testing a different drug that could be given monthly or possibly even quarterly.

Susan Sweeney, Amgen's executive vice president of obesity and related conditions, said the company sees an advantage in people not needing to take a weekly injection and instead thinking about treatment as little as four times a year.

"For somebody who's lived with obesity for a long time, it can be a major advantage in not remembering your disease," she said.

Some companies are looking beyond GLP-1 and other hot targets like GIP and glucagon to emerging areas like amylin, another hormone produced in the pancreas that helps people feel full. One company is Zealand Pharma, which presented mid-stage data from a drug called petrelintide that it's developing with Roche.

The experimental shot helped people lose almost 11% of their body weight -- less than the currently available injections Wegovy and Zepbound. But Zealand touted that fewer people taking the drug vomited than those in the placebo group.

"I truly believe that when these amylin [drugs] launch, we can have that, what I've described as an iPhone moment, because patients are so aware of the experience they have on the GLP-1s, and once you launch a new modality that gives you a better experience, people will queue up to get access to that new weight loss medication rather than staying on the more cumbersome medicines," said Zealand CEO Adam Steensberg.

Like the other potential new entrants, it will be years before Zealand's drug becomes available. Market leader Lilly is developing its own amylin analogue called eloralintide that's already in Phase 3 trials.

At this year's ADA, Lilly also presented Phase 3 results from its triple agonist retatrutide. That drug activates the GLP-1, GIP and glucagon receptors, producing dramatic weight loss.

At the highest dose, people lost an average of 28% of their body weight when they took retatrutide and stayed on it as prescribed in the trial. Lilly CEO Dave Ricks sees the drug a way to help people with a body mass index over 40, or the highest classification of obesity, achieve a healthy weight, something that's not possible if they have an average response to Lilly's current shot Zepbound.

"We showed what's possible, which is meaningful: Almost half the people lose more than 30% of their body weight," Ricks said. "So if you do start at a higher level, you can really get to a more healthy state, which is everyone's goal, I think."

Beyond Lilly and Novo?Investors are now trying to figure out whether the market will remain a duopoly between Lilly and Novo or whether the potential new entrants will become significant players. The newcomers point to the fact that about 2.5 billion people in the world are considered overweight, and 890 million are considered obese, according to statistics from the World Health Organization.

"The big question is not the volume, it's really the pricing," said Goldman Sachs analyst Asad Haider. "Where does that end up?"

Lilly and Novo have cut the price of their weight loss shots over the past year as they compete against one another and compounding pharmacies that sell less expensive knockoff versions of their drugs. Both Lilly and Novo are also trying to improve health insurance coverage of GLP-1 drugs for weight loss.

In a few weeks, millions of seniors on Medicare will be able to access the medicines for $50 a month out of pocket.

Novo Nordisk CEO Mike Doustdar thinks that in the coming years obesity will look like mental health once did, where people labeled it as one condition.

"Today that's depression, to bipolar, to schizophrenia, to many, many different issues with very distinct, different medications, and support for the patients. We view obesity that way," he said.

With so many drugs in the pipeline, the future of treating obesity, and who uses which treatment, could look very different. At least that's what drugmakers trying to gain a bigger share of the market hope.

HomeStock IdeasLong IdeasTech 

SummaryBroadcom (AVGO) remains highly attractive despite a 20% post-earnings pullback, as margin compression is driven by product mix, not structural weakness.In reality, the Q3 gross margin guidance of 74% reflects a large $10B XPU shipment, confirming temporary margin pressure rather than deteriorating unit economics.AI revenues are projected to grow at 2x industry CAGR, with AI now comprising nearly half of AVGO's total revenues and supporting 62-66% annual growth rates.I reiterate my Bullish rating, viewing current valuation at 17.6x EV/sales as cheap given robust AI demand and margin equilibrium between software and semiconductors. J Studios/DigitalVision via Getty Images

Investment Thesis As June began, markets were excited about Broadcom’s (AVGO) Q2 ER.

The company has been the biggest beneficiary of the XPU market that is growing at near 30% CAGRs because hyperscalers

6.74K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in AVGO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Starboard Value, the activist hedge fund led by Jeff Smith, fully exited its positions in Salesforce (NYSE:CRM | CRM Price Prediction) and Autodesk (NASDAQ:ADSK) during the first quarter of 2026, disclosed in a 13F filed May 15, 2026. In their place, Smith opened brand-new long positions in Lamb Weston (NYSE:LW) and CarMax (NYSE:KMX), and added to existing stakes in Riot Platforms and TripAdvisor.

From Software Activism to Old-Economy Turnarounds Starboard’s Salesforce campaign began in late 2022 and pushed Marc Benioff toward margin expansion and discipline. Three years later, the thesis cashed in. Salesforce just posted Q1 FY27 EPS of $3.88 versus a $3.13 consensus, funded a $25 billion accelerated share repurchase, and cut diluted share count to 871 million from 970 million. The activist work was effectively done. CRM is now down around 35% year to date, suggesting Smith trimmed before the broader software valuation reset accelerated.

The rotation is what’s striking. Smith abandoned two enterprise-software names and pivoted into frozen french fries and used cars, two of the more distressed corners of the consumer economy.

The Lamb Weston and CarMax Thesis Lamb Weston is the classic Starboard setup. The stock is down nearly 46% over five years, trades at a forward P/E of 13 and is mid-restructuring. The “Focus to Win” plan targets more than $250 million of savings by fiscal year-end 2028. The company posted Q3 FY26 adjusted EPS of 72 cents versus the 61-cent consensus — a third straight beat — and raised FY26 net sales guidance to $6.45 billion to $6.55 billion. Operational momentum is real, but profitability remains compressed: GAAP net income fell 63% year over year on restructuring charges and a raw potato write-off.

CarMax is even more distressed. Shares are down nearly 56% over five years. Starboard previously disclosed a $350 million stake and nominated two directors, pushing for a better digital experience, faster cost cuts, dynamic pricing, and roughly $300 million in identified savings. New CEO Keith Barr took over March 16, 2026 and raised the SG&A exit-rate reduction target to $200 million. KMX has rallied 26% year to date, indicating the market is starting to price in execution.

Smaller Adds: Riot and TripAdvisor Riot Platforms has surged 90% year to date as its pivot to AI data center hosting takes hold, anchored by an AMD lease worth $636 million over 10 years. TripAdvisor recorded $3.3 million in shareholder activism costs in Q1, signaling an engaged activist, though no fund is named in the filing.

Should Retail Investors Follow? Smith’s pattern is consistent: enter distressed names with identifiable cost-out catalysts, then push management toward execution. CarMax already shows the activist fingerprint: new CEO, raised savings target, board reshuffle. Lamb Weston has the operational rigor but lacks confirmed activist demands. For a retirement-focused investor, KMX offers the cleaner activist roadmap, while LW carries higher idiosyncratic risk through ongoing ERP-related securities litigation and price/mix pressure. The more durable lesson is understanding why Smith left CRM (job done) and why he’s buying potatoes and used cars (job beginning).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lucid Group To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Lucid Group between February 25, 2026 and April 13, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lucid Group, Inc. (“Lucid Group” or the “Company”) (NASDAQ: LCID) and reminds investors of the July 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (2) the foregoing was likely to, and did, have a material negative impact on the Company’s business and financial results; (3) accordingly, the Defendants had overstated the purported enhancements to Lucid’s manufacturing and delivery capabilities and overall operations; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Lucid Group’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Lucid Group class action, go to www.faruqilaw.com/LCID or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Lucid Group, Inc. Securities Class Action Lawsuit:

What is the Lucid Group securities fraud lawsuit about?
The Lucid Group securities fraud lawsuit is a federal securities class action alleging that Lucid Group, Inc. (NASDAQ: LCID) and its executives made false and misleading statements to investors by concealing that a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity SUV and overstating the Company's manufacturing and delivery capabilities. As the truth emerged through a series of disclosures — including an April 3, 2026 announcement that only 3,093 vehicles were delivered in Q1 2026 due to a 29-day delivery disruption caused by a supplier seat defect, an April 14, 2026 filing revealing Q1 revenue of just $280–$284 million against a consensus estimate of $433.8 million and a $1.05 billion capital raise, and a May 5, 2026 earnings report showing a net loss of over $1 billion and GAAP EPS of -$3.46 — LCID's stock price fell sharply across multiple trading sessions, causing significant losses for investors.

Who may be eligible to participate in the Lucid Group class action lawsuit?
Investors who purchased or acquired Lucid Group, Inc. (LCID) stock between February 25, 2026 and April 13, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the Lucid Group securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Lucid Group employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Lucid Group lawsuit?
A lead plaintiff in the Lucid Group class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any Lucid Group investor who purchased LCID stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 28, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Lucid Group stock during the Class Period?
Investors who purchased Lucid Group, Inc. (LCID) stock between February 25, 2026 and April 13, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Lucid Group securities class action is July 28, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/LCID for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f60c456-51b6-4096-a862-d5d3beda6cc5

Weekly Market HighlightsThe week reflected a mixed performance in the market, with 647 stocks gaining more than 10% while 933 stocks declined by more than 10%, underscoring significant volatility.Overall market breadth favored advancers with 5,437 stocks rising compared to 4,060 falling, while the mean weekly return was 5.79% and the median return was 0.8%, indicating a skew towards more modest gains among a majority of stocks.For the week, S&P 500 (SPY) gained 0.57%, Nasdaq (QQQ) gained 2.31%, and Dow Jones Industrial Average (DIA) gained 0.66%.The best-performing sectors were Consumer Cyclical, up 3.98%, Basic Materials, up 3.28%, and Consumer Defensive, up 2.43%. Market News HighlightsSpaceX IPO raises $75 billion on Friday (Jun 11): SpaceX SPCX made its historic NASDAQ debut at $135 per share, achieving a valuation of $1.8 trillion, making it the largest IPO in history and contributing to significant wealth for thousands of employees. Source: CNBC.GSK acquires Nuvalent for $10.6 billion on Thursday (Jun 9): GlaxoSmithKline GSK has agreed to acquire Nuvalent NUVL in an all-cash deal, marking a significant expansion into lung cancer treatments. Source: CNBC.Oracle stock plummets on funding announcement: Oracle ORCL announced plans to raise $40 billion for data center expansion, resulting in a more than 10% drop in stock price despite beating earnings expectations. Source: CNBC.President Trump comments on inflation surge: President Trump stated he "loves the inflation" as annual inflation reached its highest level in three years, linking rising prices to geopolitical tensions in Iran. Source: NBC News.Broad market rallies amid peace hopes: Global stock indices saw significant gains following signals of a potential Iran ceasefire, with major indices rising over 1.7% on Tuesday (Jun 10). Source: CNBC.AI stocks rebound with Nvidia leading the charge: Nvidia NVDA confirmed an expanded collaboration with SK Hynix to supply AI chips, contributing to a broader recovery in AI-related stocks this week. Source: Fortune.Airline profits suffer amid fuel cost surge: The International Air Transport Association has reduced its 2026 profit forecasts for airlines by nearly half, citing rising jet fuel costs driven by Middle Eastern conflicts. Source: AP News.EU raises interest rates in response to inflation: The European Central Bank hiked rates to 2.25%, the first increase in over a year, attributed to energy-driven inflation from the Iran conflict. Source: CNBC.AI IPOs on the horizon create market buzz: Upcoming IPOs from AI firms such as OpenAI and Anthropic are anticipated to fuel market activity, raising concerns among analysts about liquidity and valuation bubbles. Source: Fortune.Nvidia announces 25-fold dividend hike: Nvidia (NVDA) has increased its quarterly dividend significantly, reflective of robust ongoing financial performance driven by AI growth. Source: Motley Fool.McDonald's incident highlights employee safety concerns: A McDonald’s employee in California was injured in an altercation, drawing attention to safety measures within fast-food environments. Source: NBC News.Paramount-Warner Bros. merger receives DOJ approval: The U.S. Department of Justice cleared Paramount's (PSKY) $110 billion acquisition of Warner Bros. Discovery WBD , though challenges remain. Source: CNBC.Airlines warn of higher fares as costs rise: Industry executives indicated that rising oil prices and new regulations will lead to increased fares amidst profit margin pressures. Source: The Guardian.China's oil import cuts stabilize market prices: Despite escalating tensions, China’s strategies in managing oil imports have helped maintain steady prices around $94 per barrel. Source: Fortune.Supreme Court ruling impacts investor rights: A recent Supreme Court decision limits the ability of private investors to sue under the Investment Company Act, emphasizing federal regulatory oversight. Source: Newsweek.Jet fuel costs impact airline profits: The significant increase in jet fuel spending has led airlines to adjust their profit forecasts dramatically, prompting concerns about possible fare hikes for travelers. Source: AP News.Major retailers reevaluate benefits for GLP-1 medications: As the market for obesity treatments grows, large employers are reconsidering coverage for GLP-1 medications, reflecting rising healthcare costs associated with their usage. Source: Yahoo Finance.AI collaborations expand in healthcare sector: Partnerships between health tech startups and established companies like Eli Lilly (LLY) and Nvidia (NVDA) are advancing AI in clinical practices, marking a shift in healthcare documentation. Source: Fortune.Expectations build for upcoming inflation data: Market analysts are gearing up for the upcoming consumer price index report, with predictions of further inflationary pressure due to rising energy costs. Source: CNBC.```

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

HomeDividends AnalysisREITs AnalysisReal Estate Analysis

SummaryNNN REIT remains a buy for its unmatched defensive profile and disciplined acquisition strategy, favoring small, high-quality deals.NNN boasts a diversified portfolio with 3,700+ properties, 98.6% occupancy, and a 10.2-year WALT, reflecting robust tenant health and lease management.Management raised 2026 AFFO and core FFO guidance, now targeting 3.5% AFFO growth, with a conservative 68.4% payout ratio supporting 36 consecutive dividend increases.NNN trades at a 13.1x forward P/FFO, below sector peers, offering value and stability for income-focused investors despite macroeconomic and rate risks. Mongkol Onnuan/iStock via Getty Images

I've covered NNN REIT (NNN) many times before. The last time I covered it was 3 months ago. I said it was a buy. And since then, it delivered less than 5% total return.

5.09K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NNN, O, ADC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information, opinions, and thoughts included in this article do not constitute an investment recommendation or any form of investment advice.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Capital One is rated buy as the Discover integration creates scale, despite a 27% YTD stock decline. COF now commands a 24% credit card revenue share, surpassing Visa and Mastercard standalone, with efficiency ratio improvements expected. Credit risk remains the key concern, but delinquency and net charge-off ratios are stabilizing post-Discover, supporting a positive outlook.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Commvault To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Commvault between April 29, 2025 and January 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - June 13, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Commvault Systems, Inc. ("Commvault" or the "Company") (NASDAQ: CVLT) and reminds investors of the July 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Defendants provided investors with material information pertaining to Commvault's projected ARR growth for fiscal year 2026. Defendants' statements included, among other things, misleading guidance and projections related to the Company's new net ARR growth. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Commvault's ARR growth environment; pertinently, Commvault knew or recklessly disregarded that the Company's ARR growth guidance failed to properly factor in crucial variables, such as the type of sale. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Commvault's securities at artificially inflated prices.

On January 27, 2026, Commvault reported financial results for the third quarter of fiscal 2026 ended December 31, 2025, including "40% growth in SaaS ARR to $364 million," as noted by the Company's Chief Accounting Officer ("CAO") during the earnings call to discuss these results. Additionally, the CAO said "60% of our deals actually closed in the last few weeks of the quarter." According to Bloomberg Intelligence, "SaaS ARR growth of 40% represents a meaningful deceleration from 56%" reported for the second quarter fiscal 2026.

Following this news, Commvault stock declined over 31% on January 27, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Commvault's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Commvault class action, go to www.faruqilaw.com/CVLT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Commvault Systems Securities Class Action Lawsuit:

What is the Commvault Systems securities fraud lawsuit about?

The Commvault Systems securities fraud lawsuit is a federal securities class action alleging that Commvault Systems, Inc. (NASDAQ: CVLT) and its executives made false and misleading statements to investors by providing materially misleading guidance and projections related to the Company's annual recurring revenue (ARR) growth while concealing that its ARR growth guidance failed to properly account for crucial variables - such as the type of sale - that significantly affected the Company's true growth trajectory. As the truth emerged on January 27, 2026, when Commvault reported Q3 fiscal 2026 results showing SaaS ARR growth of only 40% - a meaningful deceleration from 56% in the prior quarter - CVLT's stock price fell over 31% in a single day, causing significant losses for investors.

Who may be eligible to participate in the Commvault Systems class action lawsuit?

Investors who purchased or acquired Commvault Systems (CVLT) stock between April 29, 2025 and January 26, 2026 - the Class Period - and suffered financial losses may be eligible to participate in the Commvault securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Commvault employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Commvault Systems lawsuit?

A lead plaintiff in the Commvault Systems class action is a court-appointed investor - typically the one with the largest financial interest in the case - who directs and oversees the litigation on behalf of all class members. Any Commvault investor who purchased CVLT stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 17, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Commvault Systems stock during the Class Period?

Investors who purchased Commvault Systems (CVLT) stock between April 29, 2025 and January 26, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Commvault Systems securities class action is July 17, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/CVLT for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301299

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Graphic Packaging To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Graphic Packaging between February 4, 2025 and February 2, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - June 13, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Graphic Packaging Holding Company ("Graphic Packaging" or the "Company") (NYSE: GPK) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (2) Defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (3) Defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (4) accordingly, the Company's previously issued FY 2025 financial guidance was unreliable and/or unrealistic; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Graphic Packaging's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Graphic Packaging class action, go to www.faruqilaw.com/GPK or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Graphic Packaging Holding Company Securities Class Action Lawsuit:

What is the Graphic Packaging securities fraud lawsuit about?

The Graphic Packaging securities fraud lawsuit is a federal securities class action alleging that Graphic Packaging Holding Company (NYSE: GPK) and its executives made false and misleading statements to investors by concealing significant inventory management issues, reduced demand and volumes, and increased costs, while overstating the strength and sustainability of the Company's business model and issuing unreliable financial guidance. As the truth emerged through a series of disclosures - including a May 1, 2025 Q1 earnings miss and sweeping downward revision to FY 2025 guidance, a December 8, 2025 announcement of accelerated inventory reductions, further guidance cuts, and the CEO's departure, and a February 3, 2026 Q4 earnings miss accompanied by a projected meaningful decline in 2026 adjusted EBITDA and the launch of a comprehensive business review - GPK's stock price fell sharply across each disclosure, causing significant cumulative losses for investors.

Who may be eligible to participate in the Graphic Packaging class action lawsuit?

Investors who purchased or acquired Graphic Packaging Holding Company (GPK) stock between February 4, 2025 and February 2, 2026 - the Class Period - and suffered financial losses may be eligible to participate in the Graphic Packaging securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Graphic Packaging employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Graphic Packaging lawsuit?

A lead plaintiff in the Graphic Packaging class action is a court-appointed investor - typically the one with the largest financial interest in the case - who directs and oversees the litigation on behalf of all class members. Any Graphic Packaging investor who purchased GPK stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 6, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Graphic Packaging stock during the Class Period?

Investors who purchased Graphic Packaging Holding Company (GPK) stock between February 4, 2025 and February 2, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Graphic Packaging securities class action is July 6, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/GPK for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301303

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us